Nobel Laureate Jim Allison, Ph.D., invented immune checkpoint blockade immunotherapy by blocking the CTLA-4 protein on T cells, freeing those killer immune cells to attack cancer. Now Allison and colleagues have shown that thwarting CTLA-4 also liberates T cells to assume new identities, including one that’s vital to an effective response against tumors.
In a paper in the April edition of Immunity, the researchers show that CTLA...
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...
International recognition continues to accumulate for Jim Allison, Ph.D., for opening up an entirely new way to treat cancer by freeing the...
Immunotherapy is complex, has curative potential for some patients when given alone or combined with other drugs, and needs further support to more efficiently exploit its possibilities for cancer patients.
Those messages from two leaders in the field were delivered in a pair of reviews published recently in the prestigious scientific journals Cell and Science.
Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical...
A new research platform of MD Anderson’s Moon Shots Program will lead a collaboration with an international pharmaceutical company to develop...
James Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, was awarded the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize Saturday...
A story published last week in the Wall Street Journal reveals how immune checkpoint blockade is overcoming metastatic disease for a significant...